Aze Wilson

13PUBLICATIONS
2CO-AUTHORS
Predictive and prognostic markersAllergyInnate immunityApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Immunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jan 21, 2026
Combining Cytokine-Related Biomarkers to Better Define Tumor Necrosis Factor-α Antagonist Response in Inflammatory Bowel Disease: An Observational Cohort Study.

Eryn Rooney, Gio R Dela Cruz, Terry Ponich

|Sep 17, 2025
IL23 Receptor Polymorphism Is a Predictor of Anti-Tumour Necrosis Factor-α-Induced Paradoxical Psoriasis in Inflammatory Bowel Disease.

Navneet Natt, Monica Gindi, Gio R Dela Cruz

|May 08, 2024
Infliximab Tissue Concentrations in Patients With Stable Ulcerative Colitis Are Correlated With More Durable Infliximab-associated Disease Remission.

John Choi, Qian Wang, Melanie Beaton

|Sep 28, 2022
Editorial: the immunogenicity to second anti-TNF therapy (IMSAT) therapeutic drug monitoring study-defining the risk of the in-class switch.

Aze Suzanne Wilson

|Sep 16, 2022
Decreased Infliximab Concentrations in Patients With Inflammatory Bowel Disease Who Carry a Variable Number Tandem Repeat Polymorphism in the Neonatal Fc Receptor or Variant HLADQA1*05G>A Genotype.

Bethany Choi, Michael Sey, Terry Ponich

|Jul 27, 2021
A Comparative Analysis of Drug Therapy, Disease Phenotype, and Health Care Outcomes for Men and Women with Inflammatory Bowel Disease.

Emily M Heath, Richard B Kim, Aze Wilson

Pageof 3

Frequent Collaborators

4 joint publications

Richard B Kim

1 joint publications

Maria Mikail